27 2024.10
Priority Review Granted to BLA of RemeGen’s Telitacicept for Its Third Indication of Myasthenia Gravis
15 2024.10
BLA Accepted and Priority Review Granted to Disitamab Vedotin for Its Third Indication of HER2-Positive Advanced Breast Cancer with Liver Metastasis
13 2024.08
BLA on Agenda: A Phase III Trial on Telitacicept for Myasthenia Gravis Achieves Primary Endpoint in China
05 2024.08
First Patient In Achieved in the Global Multicenter Phase III Trial on Telitacicept for Myasthenia Gravis
23 2024.07
IND of Telitacicept for Membranous Nephropathy Cleared by CDE
28 2024.06
The Data of Disitamab Vedotin for Treatment of Breast Cancer Published in Cancer Communications
02 2024.04
RemeGen's Telitacicept Granted Fast Track Designation by US FDA for Treatment of Primary Sjögren's Syndrome Following Permission of the Phase 3 Multicenter Global Clinical Trial
10 2024.03
RemeGen Gives Oral Presentation on Phase 2 Clinical Study Data of Disitamab Vedotin for Cervical Cancer at ESGO 2024
10 2024.01
JPM Healthcare Conference 2024|Dr. Fang Jianmin’s Speech: Promote the Global Development of Telitacicept at Full Speed and Create a Pioneer Blockbuster Drug in the Field of B Cell-mediated Autoimmunity
08 2024.01
RemeGen’s ADC RC88 Targeting MSLN in Patients with Ovarian Cancer and Other Tumors Obtained FDA Fast Track Designation